BASELINE CLINICAL AND PET‐CT TUMOR BURDEN PARAMETERS DO NOT PREDICT OUTCOME OF RELAPSE/REFRACTORY AGGRESSIVE B CELL LYMPHOMA PATIENTS TREATED WITH ANTI‐CD19 CAR T‐CELLS. (12th June 2019) - Avigdor, A.; Davidson, T.; Shimoni, A.; Yerushalmi, R.; Shem‐Tov, N.; Danylesko, I.; Itzhaki, O.; Toren, A.; Jacoby, E.; Besser, M.; Nagler, A.